Reimbursement & Coding of CytoSorb Therapy
You can find out here in which countries CytoSorb therapy can be specifically coded and billed. For information on countries not listed here, please contact us.
Coding of COVID-19 patients
WHO has assigned a temporary diagnoses code for COVID-19 patients: ICD U07.1.
• U07.1 COVID-19, virus identified by laboratory test and
• U07.2 COVID-19, virus not identified
Please select:
Coding of CytoSorb
The CytoSorb therapy is coded with the procedure code 8-821.2 “Extracorporeal adsorption of low and medium sized molecular, hydrophobic substances (including cytokine adsorption)”.
>> Link to the OPS Code Catalog 2022 of the DIMDI
Reimbursement of CytoSorb
According to Appendix 6 of the current German DRG catalogue, the OPS code 8-821.2 is assigned the individually, annually negotiable additional reimbursement ZE2022-09.
Please note that the additional reimbursement ZE2022-09 is split into two treatment procedures that are assigned to it; on the one hand, classic hemoperfusion (e.g., with activated charcoal filters), documented by OPS code 8-856. On the other hand, the CytoSorb therapy to be coded by OPS code 8-821.2. For easier budget negotiations, differentiation and documentation of the different reimbursement rates, the reimbursement code could be extended by a letter, for example:
ZE code OPS code
ZE2022-09-a 8-821.2 Extracorporeal adsorption of low and medium sized molecular, hydrophobic substances
ZE2022-09-b 8-856 Hemoperfusion
The CytoSorb therapy is coded with the procedure code 8-821.2 “Extracorporeal adsorption of low and medium sized molecular, hydrophobic substances (including cytokine adsorption)”.
>> Link to the OPS Code Catalog 2021 of the DIMDI
Reimbursement of CytoSorb
According to Appendix 6 of the current German DRG catalogue, the OPS code 8-821.2 is assigned the individually, annually negotiable additional reimbursement ZE2021-09.
Please note that the additional reimbursement ZE2021-09 is split into two treatment procedures that are assigned to it; on the one hand, classic hemoperfusion (e.g., with activated charcoal filters), documented by OPS code 8-856. On the other hand, the CytoSorb therapy to be coded by OPS code 8-821.2. For easier budget negotiations, differentiation and documentation of the different reimbursement rates, the reimbursement code could be extended by a letter, for example:
ZE code OPS code
ZE2021-09-a 8-821.2 Extracorporeal adsorption of low and medium sized molecular, hydrophobic substances
ZE2021-09-b 8-856 Hemoperfusion
Coding of CytoSorb
The CytoSorb therapy is coded with the procedure code 8-821.2 “Extracorporeal adsorption of low and medium sized molecular, hydrophobic substances (including cytokine adsorption)”.
>> Link to the OPS Code Catalog 2020 of the DIMDI
Reimbursement of CytoSorb
According to Appendix 6 of the current German DRG catalogue, the OPS code 8-821.2 is assigned the individually, annually negotiable additional reimbursement ZE2020-09.
Please note that the additional reimbursement ZE2020-09 is split into two treatment procedures that are assigned to it; on the one hand, classic hemoperfusion (e.g., with activated charcoal filters), documented by OPS code 8-856. On the other hand, the CytoSorb therapy to be coded by OPS code 8-821.2. For easier budget negotiations, differentiation and documentation of the different reimbursement rates, the reimbursement code could be extended by a letter, for example:
ZE code OPS code
ZE2020-09-a 8-821.2 Extracorporeal adsorption of low and medium sized molecular, hydrophobic substances
ZE2020-09-b 8-856 Hemoperfusion
We would like to inform you that the German Society for Nephrology (DGfN) as well as the German Society for Medical Controlling (DGfM) present the adsorption of hydrophobic, low and medium molecular weight substances (CytoSorb therapy) with clear statements as an independent method. Thus, this method can be clearly distinguished from other extracorporeal methods.
- In its current 2021 coding guideline, the DGfN clearly states in section 5.2.6 Monocausal Coding that adsorption of hydrophobic, low- and medium-molecular-weight substances is an independent therapeutic procedure and must be methodologically differentiated from other extracorporeal methods (e.g., hemofiltration, hemodialysis, hemodiafiltration, ECMO, heart-lung machine).
The 2021 Coding Guide is available free of charge as a pdf on the DGfN website
>> Link to Coding Guide - In response to a request, the DGfM’s Technical Committee on Proper Coding and Billing (FoKA) published a recommendation in June 2021 that the removal of hydrophobic, low- and medium-molecular-weight substances is a treatment method independent of renal replacement procedures or circulatory support procedures with extracorporeal circulation, since the materials used, indications, and treatment goals differ.
The complete request and statement can be read here:
>> Link to complete request
The CytoSorb therapy is to be coded, since 1 January 2020, via CHOP-code 99.76.31 „Extracorporeal adsorption of hydrophobic, low- and medium-sized molecular substances. Adsorption of interleukins. Adsorption of cytokines“.
>> Swiss Operational Classification (CHOP) 2022 of the FSO
All CytoSorb treatments are to be coded via CHOP 99.76.31 regardless of the indication or target substance for removal. Prior to 2020 there were different CHOP codes depending on the target substance of removal (please see “Switzerland 2019” above for further information).
>> Download Flyer CytoSorb Coding Switzerland (DE)
>> Download Flyer CytoSorb Coding Switzerland (FR)
The CytoSorb therapy is to be coded, since 1 January 2020, via CHOP-code 99.76.31 „Extracorporeal adsorption of hydrophobic, low- and medium-sized molecular substances. Adsorption of interleukins. Adsorption of cytokines“.
>> Swiss Operational Classification (CHOP) 2021 of the FSO
All CytoSorb treatments are to be coded via CHOP 99.76.31 regardless of the indication or target substance for removal. Prior to 2020 there were different CHOP codes depending on the target substance of removal (please see “Switzerland 2019” above for further information).
>> Download Flyer CytoSorb Coding Switzerland (DE)
>> Download Flyer CytoSorb Coding Switzerland (FR)
The CytoSorb therapy is to be coded, since 1 January 2020, via CHOP-code 99.76.31 „Extracorporeal adsorption of hydrophobic, low- and medium-sized molecular substances. Adsorption of interleukins. Adsorption of cytokines“.
>> Swiss Operational Classification (CHOP) 2020 of the FSO
All CytoSorb treatments are to be coded via CHOP 99.76.31 regardless of the indication or target substance for removal. Prior to 2020 there were different CHOP codes depending on the target substance of removal (please see “Switzerland 2019” above for further information).
The CytoSorb therapy was coded from January 1, 2019 until December 31, 2019 via the CHOP Code Z99.76.12 “Adsorption of cytokines (adsorption of interleukins)”.
In version 2019 of the Swiss Operative Classification, subcategory 99.76.- “Extracorporeal immunoadsorption and adsorption of inflammatory substances” was introduced and the code 99.76.12 was added. Prior to 2019 the subcategory title 99.76.- was called “Extracorporeal immunoadsorption”.
In all applications that do not focus on cytokine removal but, for example, the removal of bilirubin (liver failure) or myoglobin (rhabdomyoyse), the CytoSorb therapy was correctly identified with the CHOP code 99.76.19 “Extracorporeal immunosorbing, other”.